Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world
Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQSUPN).
Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased costs in federal health programs.
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early data on VH184 and VH499 therapies.
For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros.
– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival –
Over the past six months, Pfizer’s shares (currently trading at $26.70) have posted a disappointing 10.2% loss, well below the S&P 500’s 3.8% gain. This might have investors contemplating their next move.
Sen. Elizabeth Warren and other lawmakers raised concerns about Robert F. Kennedy Jr.'s private dinners with pharmaceutical executives at Mar-a-Lago, questioning his commitment to reducing corporate influence as Secretary of Health and Human Services.
BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key data updates expected in 2025.
PHILADELPHIA, March 05, 2025 (GLOBE NEWSWIRE) -- Berger Montague advises shareholders of Pfizer Inc. (“Pfizer” or the “Company”) (NYSEPFE) about an investigation into Pfizer’s Board of Directors for potential breaches of fiduciary duties to Pfizer and its shareholders in connection with the Company’s marketing and sale of Depo-Provera.
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Monday and uncover the stocks that are leading the way in terms of trading volume and market attention.
In light of potential tariff threats from President Donald Trump, Pfizer Inc.'s (PFE.N) CEO Albert Bourla has suggested the possibility of shifting the company's overseas manufacturing to its U.S. facilities.
